Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study

Purpose: To study the differences in the prevalence, risk, and grade of control of different cardiometabolic comorbidities in patients with primary aldosteronism (PA) and essential hypertension (EH) matched by age, sex, and blood pressure levels at diagnosis.Methods: Case-control study of a secondary base (PA patients in follow-up in a tertiary hospital between 2018-20). Controls were patients with EH, matched by age, sex, and baseline diastolic (DBP) and systolic blood pressure (SBP). Results: Fifty patients with PA and 50 controls were enrolled in the study. At diagnosis, PA patients had a higher prevalence of chronic kidney disease (CKD) than controls (18.4% vs. 2.1%, P=0.008). No differences were detected in the prevalence of other cardiometabolic comorbidities nor in their degree of control (P>0.05). All patients received antihypertensive medical treatment and 10 PA patients underwent unilateral laparoscopic adrenalectomy.After a median follow-up of 31.9 [IQR=1.0-254.8] months, PA patients presented a greater degree of declination of kidney function than controls (Average decrease in glomerular filtration rate (MDRD-4) -17.6±3.1 vs -2.8±1.8 ml/min/1.73m2, PConclusions: PA patients have a prevalence of CKD ten times higher than those with EH matched by age, sex, and blood pressure levels. Furthermore, the risk of kidney function impairment throughout the follow-up is significantly greater in PA patients and is independent of the degree of blood pressure control.